Targeted combo aims at tough lymphoma subtype
NCT ID NCT07677813
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy improves outcomes for people with a specific genetic subtype of diffuse large B-cell lymphoma (MCD subtype). Participants receive the drug combination during initial treatment, followed by orelabrutinib alone as maintenance therapy. The study tracks how long people live without the cancer worsening and monitors side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
orelabrutinib combined with R-CHOP or POLA-R-CHP chemotherapy
What this could lead to
If successful, this approach could offer a more effective treatment option for people with a specific genetic subtype of aggressive lymphoma.
What could go wrong
This is an early-phase, single-center study with a small number of participants, so results may not apply broadly. The drug combination may cause side effects, and the trial may not show a clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, 130021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••